
Retatrutide (RT-GLP3)
Triple-receptor research peptide (GLP-1/GIP/glucagon). Lyophilised vial for reconstitution.
Studied for
- Activates three receptors at once — GIP, GLP-1 and glucagon — beyond what any dual agonist targets
- 28.7% mean body-weight loss at 68 weeks, 12 mg dose — the highest yet recorded in a Phase 3 obesity trial (TRIUMPH-4)
- ~75% reduction in knee pain among the TRIUMPH-4 knee-osteoarthritis trial population
- Glucagon-receptor activity adds liver-fat and energy-expenditure research on top of the GLP-1 effect




